mbiomics has closed the third and final part of its Series A funding, adding €12 million and bringing the total to €30 million. Existing investors MIG Fonds and Bayern Kapital continued their support in this round.
The company was founded in Munich in 2020 by Dr. Laura Figulla, Dr. Markus Rinecker, and Dr. Johannes B. Woehrstein. It focuses on developing live biotherapeutic products for serious and long-term diseases. Its goal is to bridge the gap between early research and large-scale drug production.
The Series A round was divided into three stages to support the cost of building its own manufacturing setup. With the final tranche now complete, mbiomics has finished this phase of infrastructure development.
Faecal microbiota transplants (FMT) have shown strong results in clinical use. They highlight how changes in the microbiome can help treat disease. However, FMTs are difficult to standardise, hard to scale, and face growing regulatory limits.
mbiomics is working on its own platform that combines AI, machine learning, data analysis, co-cultivation, and screening methods. This approach helps design controlled microbial products.
Its lead program, MBX-116, is being developed as an add-on treatment for patients with advanced melanoma who are receiving immune checkpoint inhibitors. This group often shows low response rates, even though the microbiome plays a role in immune function.
The company is also exploring treatments for autoimmune and neurodegenerative conditions. Interest in these areas is rising as more studies point to links between the gut, brain, and immune system.
Other companies in this field include Vedanta Biosciences, Enterome, and 4D Molecular Therapeutics. In cancer-focused microbiome research, Microbiotica and Synlogic are also active. However, scaling production remains a key challenge across the sector, and mbiomics aims to address this.
The new funds will support further research, expansion of GMP manufacturing, and steps toward clinical testing. A Phase 1B study for MBX-116 is planned for 2027.
Business Outstanders brings you sharp insights on tech, business, entrepreneurship, law, crypto, and more. We uncover what’s next. Stay updated, sign up for our newsletter and be part of the future!
